M Morgan-Cox

Affiliations

Eli Lilly and Company, Indianapolis, IN, U.S.A.

Réseau de co-auteurs

MaryAnn Morgan-Cox 2 collaborations

K Reich 1 collaboration

P Rich 1 collaboration

C Maari 1 collaboration

R Bissonnette 1 collaboration

C Leonardi 1 collaboration

A Menter 1 collaboration

A Igarashi 1 collaboration

P Klekotka 1 collaboration

D Patel 1 collaboration

J Li 1 collaboration

J Tuttle 1 collaboration

E Edson-Heredia 1 collaboration

S Friedrich 1 collaboration

K Papp 1 collaboration

None None 1 collaboration

William J Sandborn 1 collaboration

Marc Ferrante 1 collaboration

Bal R Bhandari 1 collaboration

Elina Berliba 1 collaboration

Brian G Feagan 1 collaboration

Toshifumi Hibi 1 collaboration

Jay L Tuttle 1 collaboration

Paul Klekotka 1 collaboration

Stuart Friedrich 1 collaboration

Michael Durante 1 collaboration

Janelle Laskowski 1 collaboration

Jochen Schmitz 1 collaboration

Geert R D'Haens 1 collaboration

Andrew Blauvelt 1 collaboration

Jacob P Thyssen 1 collaboration

Emma Guttman-Yassky 1 collaboration

Thomas Bieber 1 collaboration

Esther Serra-Baldrich 1 collaboration

Eric Simpson 1 collaboration

David Rosmarin 1 collaboration

Hany Elmaraghy 1 collaboration

Eric Meskimen 1 collaboration

Chitra R Natalie 1 collaboration

Zhuqing Liu 1 collaboration

Chenjia Xu 1 collaboration

Evangeline Pierce 1 collaboration

Esther Garcia Gil 1 collaboration

Jonathan I Silverberg 1 collaboration

M Morgan-Cox

Affiliations

Publications (3)

Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate-to-severe plaque psoriasis: results from a randomized phase II study.

Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis.

Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials.

Réseau de co-auteurs